Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3018250 in proximal deep vein thrombosis
NL-OMON59584Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of inclocibart in deep vein thrombosis (DVT), sponsored by Bayer. Primary endpoints: AUCn(6h-30d) of ratio to baseline of clot burden and Composite of major and clinically relevant non-major bleeding events. Started Mar 2024; status: completed.
02
Drugs
inclocibart
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NL-OMON59584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59584.